Newronika Appoints Keith Carlton as Executive Chairman to Strengthen Strategic Leadership
Newronika, the pioneering company behind adaptive deep brain stimulation technology (AlphaDBS™), has appointed Keith Carlton as its new executive chairman, effective immediately. Carlton brings extensive experience in the medical device and neuromodulation sectors, where he has consistently driven innovation, strategic growth, and operational excellence. His leadership is anticipated to play a crucial role in Newronika’s next phase of global expansion.
Lorenzo Rossi, PhD, co-founder and CEO of Newronika, expressed enthusiasm about Carlton’s appointment, stating, "We are honored to welcome Keith as our executive chairman. His strategic vision and remarkable experience in commercializing innovative medical technologies will be pivotal as we look to validate and launch AlphaDBS, our exclusive system for deep brain stimulation that adapts in real-time to patient needs. This innovative platform is designed to provide targeted therapy that enhances symptom relief while minimizing side effects for patients suffering from Parkinson’s disease, simultaneously strengthening Newronika’s global presence and impact."
Carllo Sanfilippo, Senior Investment Officer at Indaco Venture Partners and a board member at Newronika, added his welcome, affirming confidence in Carlton’s leadership skills to guide the company towards its next growth phase.
In his own words, Carlton stated, "It is a privilege to join Newronika at such a critical juncture in its history. The company’s pioneering adaptive DBS technology has the potential to redefine the standard of care for Parkinson’s disease and other neurological disorders. I look forward to collaborating with the board and our talented team to accelerate innovation, expand patient access, and make a significant global impact, with an immediate priority of supporting the successful launch of the pivotal Phase III trial in the United States."
Carlton’s appointment comes at a time when Newronika is solidifying its recent achievements, including receiving CE marking approval for AlphaDBS, FDA IDE authorization, and closing a €13.6 million Series B funding round, further emphasizing its commitment to transforming the neuromodulation therapy landscape globally.
Newronika, a spin-off from the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and the University of Milan, is revolutionizing deep brain stimulation with adaptive technology that utilizes real-time neurophysiological feedback to optimize therapy. Headquartered in Milan, Italy, Newronika is dedicated to advancing adaptive DBS, with ongoing regulatory approvals and clinical initiatives in Europe, the United States, and other regions.
For media inquiries, please contact:
Lorenzo Rossi, PhD, Co-founder and CEO
Email: [email protected]
Website: www.newronika.com
Lorenzo Rossi, PhD, co-founder and CEO of Newronika, expressed enthusiasm about Carlton’s appointment, stating, "We are honored to welcome Keith as our executive chairman. His strategic vision and remarkable experience in commercializing innovative medical technologies will be pivotal as we look to validate and launch AlphaDBS, our exclusive system for deep brain stimulation that adapts in real-time to patient needs. This innovative platform is designed to provide targeted therapy that enhances symptom relief while minimizing side effects for patients suffering from Parkinson’s disease, simultaneously strengthening Newronika’s global presence and impact."
Carllo Sanfilippo, Senior Investment Officer at Indaco Venture Partners and a board member at Newronika, added his welcome, affirming confidence in Carlton’s leadership skills to guide the company towards its next growth phase.
In his own words, Carlton stated, "It is a privilege to join Newronika at such a critical juncture in its history. The company’s pioneering adaptive DBS technology has the potential to redefine the standard of care for Parkinson’s disease and other neurological disorders. I look forward to collaborating with the board and our talented team to accelerate innovation, expand patient access, and make a significant global impact, with an immediate priority of supporting the successful launch of the pivotal Phase III trial in the United States."
Carlton’s appointment comes at a time when Newronika is solidifying its recent achievements, including receiving CE marking approval for AlphaDBS, FDA IDE authorization, and closing a €13.6 million Series B funding round, further emphasizing its commitment to transforming the neuromodulation therapy landscape globally.
About Newronika SpA
Newronika, a spin-off from the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and the University of Milan, is revolutionizing deep brain stimulation with adaptive technology that utilizes real-time neurophysiological feedback to optimize therapy. Headquartered in Milan, Italy, Newronika is dedicated to advancing adaptive DBS, with ongoing regulatory approvals and clinical initiatives in Europe, the United States, and other regions.
For media inquiries, please contact:
Lorenzo Rossi, PhD, Co-founder and CEO
Email: [email protected]
Website: www.newronika.com
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.